Mifepristone: bioavailability, pharmacokinetics and use-effectiveness (Q34540819)

2 August 2017

1 reference

title

Mifepristone: bioavailability, pharmacokinetics and use-effectiveness (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

Sarkar NN

1

1 reference

2 August 2017

1 March 2002

1 reference

European Journal of Obstetrics Gynecology and Reproductive Biology

2 August 2017

1 reference

2 August 2017

101

1 reference

2 August 2017

2

1 reference

2 August 2017

113-120

1 reference

Clinical pharmacology of RU 486--an antiprogestin and antiglucocorticoid

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Mifepristone and first trimester abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Mifepristone: clinical pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pharmacodynamics of the antiprogesterone RU486 in women after oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Mifepristone: antineoplastic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Distribution of RU 486 and its demethylated metabolites in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Plasma concentrations and receptor binding of RU 486 and its metabolites in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pharmacokinetics of mifepristone after low oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Dose-response relationships of RU 486.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pharmacokinetic study of orally administered RU 486 in non-pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Clinical Pharmacokinetics of Mifepristone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Progesterone receptors: expression and regulation in the mammalian ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Atomic structure of progesterone complexed with its receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Molecular mechanisms of action of steroid/thyroid receptor superfamily members

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

A single amino acid that determines the sensitivity of progesterone receptors to RU486.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

RU486: the French experience

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study--final results

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05--a multicentre randomized clinical trial in China

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Blood loss in termination of early pregnancy with mifepristone and gemeprost

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Blood loss with mifepristone--misoprostol abortion: measures from a trial in China, Cuba and India

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Side effects of mifepristone-misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba, and India

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Outcomes of suction curettage and mifepristone abortion in the United States. A prospective comparison study.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Early pregnancy termination with mifepristone and misoprostol in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Interruption of early pregnancy with mifepristone in combination with gemeprost

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

An effective regimen for early medical abortion: a report of 2000 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Low-dose mifepristone 200 mg and vaginal misoprostol for abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

The efficacy of medical abortion: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Misoprostol for medical evacuation of early pregnancy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Comparison between oral and vaginal administration of misoprostol on uterine contractility

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Absorption kinetics of misoprostol with oral or vaginal administration

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Hormonal anti-implantation agents: antiprogestins

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Contraception with anti-progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Effect of low weekly doses of mifepristone on ovarian function and endometrial development

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Effect of low daily doses of mifepristone on ovarian function and endometrial development

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Effect of once weekly administration of mifepristone on ovarian function in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Effects of long-term low-dose mifepristone on reproductive function in women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Contraceptive efficacy of low doses of mifepristone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Early luteal phase treatment with mifepristone (RU 486) for fertility regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

Contraceptive use of antiprogestin

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900522-X

7 January 2021

10.1016/S0301-2115(01)00522-X

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11858883